The role of thyroid peroxidase gene variant rs2175977 in subclinical hypothyroidism and autoimmune thyroid response

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-08-18 DOI:10.1016/j.cca.2025.120559

Larsa Naji Adam, Awat Mustafa Abbas

{"title":"The role of thyroid peroxidase gene variant rs2175977 in subclinical hypothyroidism and autoimmune thyroid response","authors":"Larsa Naji Adam, Awat Mustafa Abbas","doi":"10.1016/j.cca.2025.120559","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><div>Study investigated the association of the thyroid peroxidase (TPO) gene polymorphism with Subclinical hypothyroidism (SCH) risk.</div></div><div><h3>Methods</h3><div>A case-control study of 78 SCH patients SCH and 75 controls. Genomic DNA extracted from the blood, and the rs2175977 SNP in the Exon 8 of the TPO gene was genotyped through the PCR and Subsequent RFLP by SgrBI digestion. Statistics assessed genotype frequencies, allelic distributions, and associations with biochemical parameters.</div></div><div><h3>Results</h3><div>The GG genotype was significantly more in controls compared to SCH patients (p = 0.0039), while GC and CC genotypes were more prevalent in SCH. The C allele was significantly associated with increased SCH risk (p = 0.0006; OR = 0.3887). The GC and CC variant had significantly higher levels of Anti-TPO antibodies (p = 0.0429).</div></div><div><h3>Conclusion</h3><div>A TPO gene polymorphism, has been linked to increased risk of SCH and an elevated level of anti-TPO antibodies, indicating thyroid autoimmune disorder.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120559"},"PeriodicalIF":2.9000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125004383","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

Study investigated the association of the thyroid peroxidase (TPO) gene polymorphism with Subclinical hypothyroidism (SCH) risk.

Methods

A case-control study of 78 SCH patients SCH and 75 controls. Genomic DNA extracted from the blood, and the rs2175977 SNP in the Exon 8 of the TPO gene was genotyped through the PCR and Subsequent RFLP by SgrBI digestion. Statistics assessed genotype frequencies, allelic distributions, and associations with biochemical parameters.

Results

The GG genotype was significantly more in controls compared to SCH patients (p = 0.0039), while GC and CC genotypes were more prevalent in SCH. The C allele was significantly associated with increased SCH risk (p = 0.0006; OR = 0.3887). The GC and CC variant had significantly higher levels of Anti-TPO antibodies (p = 0.0429).

Conclusion

A TPO gene polymorphism, has been linked to increased risk of SCH and an elevated level of anti-TPO antibodies, indicating thyroid autoimmune disorder.

查看原文本刊更多论文

甲状腺过氧化物酶基因变异rs2175977在亚临床甲状腺功能减退和自身免疫性甲状腺反应中的作用

目的探讨甲状腺过氧化物酶（TPO）基因多态性与亚临床甲状腺功能减退（SCH）风险的关系。方法对78例SCH患者和75例对照组进行病例对照研究。从血液中提取基因组DNA，通过PCR和SgrBI消化的后续RFLP对TPO基因8外显子rs2175977 SNP进行基因分型。统计学评估了基因型频率、等位基因分布以及与生化参数的关联。结果对照组中GG基因型明显高于SCH患者（p = 0.0039），而SCH患者中GC和CC基因型明显高于对照组（p = 0.0006; OR = 0.3887）。GC和CC变体的抗tpo抗体水平显著升高（p = 0.0429）。结论TPO基因多态性与SCH风险增加和抗TPO抗体水平升高有关，提示甲状腺自身免疫性疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.